Teresa Klinowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Teresa Klinowska has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Justin P. O. Lindemann
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
25 shared publications - Christopher J. Morrow
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
24 shared publications - Alastair M. Mathewson
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
16 shared publications - Andy Sykes
DMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
16 shared publications - Oona Delpuech
The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom
16 shared publications - Anne Armstrong
The Christie NHS Foundation Trust, Manchester, United Kingdom
15 shared publications
Latest Publications
- Open Access
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open AccessOpen‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
ESR1m ctDNA dynamics for each CDK4/6i + camizestrant combination. (Top) waterfall plot showing percentage change in ESR1m summed VAF at C2D1 compared with C1D1 in each evaluable patient. (Middle) vector plot showing absolute ESR1m ctDNA change. The dots indicate the summed VAF observed in the C1D1 sample (magenta) and the C2D1 sample (black). (Bottom) tile plot of ESR1m identified in each patient by ctDNA. ESR1m was defined as a mutation that gives rise to one of the following amino acid changes: E380Q, V422del, S463P, L536H/P/R, Y537C/D/N/S, or D538G. C1D1, cycle 1, day 1; C2D1, cycle 2, day 1; nd, not detected; sVAF, summed variant allele frequency; VAF, variant allele frequency.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
ESR1m ctDNA dynamics for each CDK4/6i + camizestrant combination. (Top) waterfall plot showing percentage change in ESR1m summed VAF at C2D1 compared with C1D1 in each evaluable patient. (Middle) vector plot showing absolute ESR1m ctDNA change. The dots indicate the summed VAF observed in the C1D1 sample (magenta) and the C2D1 sample (black). (Bottom) tile plot of ESR1m identified in each patient by ctDNA. ESR1m was defined as a mutation that gives rise to one of the following amino acid changes: E380Q, V422del, S463P, L536H/P/R, Y537C/D/N/S, or D538G. C1D1, cycle 1, day 1; C2D1, cycle 2, day 1; nd, not detected; sVAF, summed variant allele frequency; VAF, variant allele frequency.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Percentage change in ESR1m variants
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Percentage change in ESR1m variants
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
ORR, CBR24, and median PFS for subgroup analysis across pooled camizestrant 75 mg combination arms
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
ORR, CBR24, and median PFS for subgroup analysis across pooled camizestrant 75 mg combination arms
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Safety summary of camizestrant
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Safety summary of camizestrant
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
AEs leading to dose reduction or discontinuation in patients treated with camizestrant 75, 150, or 300 mg combined with either abemaciclib, palbociclib, or ribociclib. Description data are presented as number and % of patients. N, number; NA, not applicable.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
AEs leading to dose reduction or discontinuation in patients treated with camizestrant 75, 150, or 300 mg combined with either abemaciclib, palbociclib, or ribociclib. Description data are presented as number and % of patients. N, number; NA, not applicable.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Time course of heart rate reductions and QTcF
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Time course of heart rate reductions and QTcF
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
ORR, CBR24, and median PFS for (A) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; (B) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arrowed line in the plots and is not representative of the data. N, no; NC, not calculated; Y, yes. Data in % represent 95% CI.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
ORR, CBR24, and median PFS for (A) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; (B) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arrowed line in the plots and is not representative of the data. N, no; NC, not calculated; Y, yes. Data in % represent 95% CI.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.